Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
OSTX
OSTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
OSTX News
OS Therapies Plans Conditional Marketing Authorization Applications by Q1 2026
Feb 17 2026
Benzinga
OS Therapies (OSTX) Reports Positive OST-HER2 Data but Shares Drop 4.52%
Jan 15 2026
Benzinga
Oncolytics Biotech Appoints New Executives to Accelerate Cancer Treatment Progress
Jan 14 2026
Globenewswire
Oncolytics Biotech Fortifies IP Protection, Extends Pelareorep Commercial Runway to 2044
Jan 08 2026
Globenewswire
OS Therapies Under Investigation for Potential Director Misconduct
Jan 05 2026
PRnewswire
Stonegate Capital Partners Revises Coverage for OS Therapies Inc. (OSTX) in Q3 2025
Nov 21 2025
Yahoo Finance
D. Boral Capital Reiterates Buy Rating on OS Therapies with $20 Price Target Intact
Nov 21 2025
Benzinga
Quantum Computing Stocks Surge Over 23%; Check Out 20 Premarket Movers
Nov 17 2025
Benzinga
OS Therapies Revises OST-HER2 Regulatory Submission Timeline, Focuses on UK MHRA MAA Application
Sep 30 2025
NASDAQ.COM
D. Boral Capital Reiterates Buy Rating on OS Therapies with $20 Price Target Intact
Sep 12 2025
Benzinga
Stonegate Capital Partners Begins Coverage of OS Therapies Inc. (OSTX)
Sep 08 2025
Yahoo Finance
Key Stocks to Monitor: IOVA Rises Following Regulatory Approval, FDA Expedites Aldeyra's Medication
Aug 19 2025
NASDAQ.COM
OS Therapies files $100M mixed securities shelf
Aug 08 2025
SeekingAlpha
D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target
Jul 03 2025
Benzinga
OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Jul 03 2025
Newsfilter
D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target
Jun 30 2025
Benzinga
Show More News
